Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.

Duncan C Gilbert\textsuperscript{1,*}, Trinh Duong\textsuperscript{1,*}, Matthew Sydes\textsuperscript{1}, Anna Bara\textsuperscript{1}, Noel Clarke\textsuperscript{2}, Paul Abel\textsuperscript{3}, Nick James\textsuperscript{4,5}, Ruth Langley\textsuperscript{1} and Max Parmar\textsuperscript{1} on behalf of the STAMPEDE and PATCH Trial Management Groups

\textsuperscript{1}MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 90 High Holborn, London WC1V 6LJ

\textsuperscript{2}Department of Urology, Christie and Salford Royal NHS Foundation Trusts, Manchester, UK

\textsuperscript{3}3N Dept of Urology, Imperial College, Charing Cross Campus, Fulham Palace Road, London W6 8RF

\textsuperscript{4}Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT

\textsuperscript{5}Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH

*equal contribution
Background

Androgen deprivation therapy (ADT) remains a cornerstone of the management of prostate cancer. The addition of ADT to radiotherapy improves disease-free and overall survival in the locally advanced setting and ADT forms the backbone onto which additional treatments may be added (either initially at first presentation or sequentially at disease progression). ADT is most commonly achieved with Gonadotrophin Releasing Hormone analogues (GnRHa) that act through the hypothalamic-pituitary-gonadal axis to prevent testicular production of testosterone. However, the therapeutic benefits of ADT are partially offset by its side-effects which include long-term osteopaenia, osteoporosis and fracture and increased risk of cardiovascular disease, weight gain and metabolic syndrome, reduced quality-of-life (including hot flushes, fatigue, sexual dysfunction and depression) and cognitive decline [1].

Although some of these unwanted effects result from the necessary reduction in testosterone levels, others are related to disturbance of the endocrine milieu, particularly oestrogen levels. Circulating oestrogens in men are produced through the peripheral conversion of testosterone. As a result of the testosterone reduction, oestrogens are therefore also suppressed, contributing to adverse effects (Figure 1).

Exogenous oestrogens will also suppress luteinizing hormone (LH) production from the pituitary via negative feedback, lowering systemic testosterone production whilst avoiding the effects of a low oestrogenic state such as osteopaenia and dysregulation of lipid and glucose metabolism. Oral
systemic oestrogens were amongst the first successful systemic therapies for advanced prostate cancer. However, systemic oral oestrogens in men are associated with an increased risk of cardiovascular and thromboembolic disease resulting from a first-pass effect in the liver with production of pro-thrombotic proteins. Transdermal application of oestradiol (tE2) avoids this effect and offers an alternative, potentially safer, means of androgen suppression with oestrogens [2].

The PATCH trial (NCT00303784), currently recruiting, compares the efficacy and safety of tE2 against GnRH Analogues in men with locally advanced and metastatic prostate cancer, and has so far recruited over 1400 men. The initial pilot phase showed tE2 achieved equivalent castration rates to GNRHa without the excess cardiovascular morbidity or mortality previously seen with oral oestrogen [3]. Subsequent analyses demonstrated a number of other potential benefits of tE2 compared to GNRHa, including improved bone mineral density [4], more favourable metabolic profiles and better quality-of-life over 6 months of ADT, though with increased likelihood of gynaecomastia [5].

Evaluating tE2 within the STAMPEDE trial

STAMPEDE (NCT002684476) is a platform (or “living”) protocol using multi-arm, multi-stage trial designs to investigate novel treatment approaches in locally advanced or metastatic hormone-sensitive prostate cancer. Opening in 2005, it has recruited nearly 10,000 patients across the UK and Switzerland, testing 10 approaches thus far, demonstrating that the addition of docetaxel and abiraterone to standard ADT each improve overall survival as well as demonstrating a lack of significant benefit with zoledronic acid and celecoxib [6]. Randomised cohorts investigating radiotherapy (to the primary tumour in the face of metastatic disease) and the combination of abiraterone and enzalutamide have completed recruitment and are in active follow-up. STAMPEDE is currently recruiting to the “metformin comparison” and since June 2017, a new “tE2 comparison” has been added comparing tE2 to standard ADT to complement the PATCH trial.
The clinical efficacy of tE2 will henceforth be assessed using data from approximately 2,000 contemporaneously randomised patients from the PATCH and STAMPEDE trials, using a meta-analysis approach (Figure 2). This strategic decision, taken by the Trial Management Groups of the trials together and with the approval of the appropriate funding bodies, allows faster recruitment to the comparison and activation of the comparison at additional UK sites. Competing or overlapping trials tend to be discouraged by Hospital R&D departments so this expands recruitment efficiently. This combined approach also reduces the number of patients allocated standard treatment (across both trials overall) thereby increasing the proportion of patients receiving a novel treatment.

Within both STAMPEDE and PATCH, and in accordance with current recommendations, radiotherapy will be mandated (unless contraindicated) for all N0 M0 patients and encouraged for N+M0 patients; use of docetaxel is permitted for all patients, including those randomised to tE2. So far, no additional toxicity has been observed in patients receiving upfront docetaxel with tE2 within PATCH (permitted since 2016); this will continue to be monitored in both trials.

A practical challenge in recruiting to a “tE2 comparison” is the requirement to limit exposure to GnRHa prior to randomisation. Prolonged duration of testosterone suppression can be seen with 12-week depot GnRHa injections. Ideally, all patients would be recruited and randomised whilst still on their pre-GnRHa, anti-flare anti-androgen, as done in PATCH, however, within STAMPEDE, trial entry is permitted within 12 weeks of starting LHRH. To accommodate this difference in approach, patients who have only received a single 4-week injection are eligible for randomisation to the “tE2 comparison”.

Conclusions

Accumulating data from the PATCH trial is building a case in support of tE2 as a potential alternative to GnRHa for the suppression of androgens in the treatment of locally advanced and metastatic prostate cancer. The incorporation of the “tE2 comparison” within STAMPEDE allows the efficacy and toxicity questions to be answered in the most efficient manner possible for patients, trialists and funders alike. The evolving STAMPEDE platform allows integration of updates in the standard of care with ongoing research questions to maximise benefits to future patients by understanding how these improvements can be combined. More broadly, if the combined analysis of PATCH and STAMPEDE confirms tE2 as a method for ADT on prostate cancer with benefits over GnRHa, this therapeutic modality could be investigated in other situations requiring ADT, such as short-term androgen suppression in combination with radiotherapy in the treatment of high risk localised disease. Transdermal oestradiol patches may also add a cost benefit: they are considerably cheaper than other systemic approaches to ADT. This could potentially have important implications for improving access to prostate cancer treatment in low and middle income countries where primary presentation with metastatic disease is common and prostate cancer incidence is rising as populations age.

Acknowledgements;

The PATCH study is funded by Cancer Research UK, C17093/A12443 (trial CRUK/06/001) and University College London (UCL), and is sponsored by Imperial College London. STAMPEDE is funded by Cancer Research UK (CRUK_A12459), Medical Research Council (MRC_MC_UU_12023/25), Astellas Pharma, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis. Ruth E. Langley has served as an advisor for, and received honoraria from Bayer. The authors report no additional conflicts of interest.
Figure Legends:

**Figure 1: tE2 and testosterone metabolism.** tE2 produces androgen suppression but replaces endogenous oestradiol lost (where 80% arises from the peripheral conversion of testosterone). tE2 therefore mitigates the oestrogenic side effects that arise with conventional ADT (LHRHa).

**Figure 2: a) trial schema and b) projected trial enrolment and contribution of data from PATCH and STAMPEDE**

References


5. Gilbert, D.C. et al. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus

a) Eligible for STAMPEDE
- Decide if planned for RT and docetaxel
- Duration of prior hormone therapy
- Maximum of one 4 weeks (or 1 month) LHRH injection (with 3-6 weeks anti-androgen)

Non-diabetic patient
Randomisation

Patient has diabetes
Randomisation

Key
A: ADT + RT + DOC
B: ADT + RT + DOC + metastasis
L: LE2 + RT + DOC

RT = Radical radiotherapy for NM+ pts
DOC = Treatment for skeletal pts
ADT = Androgen deprivation therapy
LHRH = Luteinising hormone-releasing hormone
LE2 = Metastatic androgen

b) Number of patients over time
- Combined in meta-analysis approach in 2023
- Patients from STAMPEDE
- Patients from PATCH

Graph showing the number of patients from 2016 to 2021.